NASDAQ: ALXO - ALX Oncology Holdings Inc.

Yield per half year: +44.34%
Sector: Healthcare

Share chart ALX Oncology Holdings Inc.


About

ALX Oncology Holdings Inc., иммуноонкологическая компания на клинической стадии, специализируется на разработке методов лечения пациентов, борющихся с раком. Его ведущим продуктом-кандидатом является ALX148, блокирующий CD47 терапевтический препарат, используемый для лечения миелодиспластических синдромов и острого миелоидного лейкоза, а также ряда показаний к солидным опухолям, включая плоскоклеточную опухоль головы и шеи и человеческий эпидермальный рецептор фактора роста 2, положительный для карциномы желудочно-пищеводного перехода.

More details
Компания была основана в 2015 году и базируется в Берлингейме, штат Калифорния.


Main settings

P/S 2844.74
P/BV 2.47
EV/EBITDA 0.1917
EBITDA -0.0188
Цена ао 13.38
Сайт http://www.alxoncology.com
Число акций ао 0.04299 млрд
Выручка 0.0048
Див.доход ао 0
ISIN US00166B1052
Change price per day: 0% (13.38)
Change price per week: +9.4% (12.23)
Change price per month: +8.16% (12.37)
Change price per 3 month: -6.69% (14.34)
Change price per half year: +44.34% (9.27)
Change price per year: +175.88% (4.85)
Change price per 3 year: -74.37% (52.2)
Change price per year to date: -14.4% (15.63)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 2844.74 4
P/BV 2.47 5
P/E 0 0
EV/EBITDA 0.1917 0
Total:

Efficiency

Title Value Grade
ROA, % -58.58 0
ROE, % 236.9 10
Total:

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total:

Debt

Title Value Grade
Debt/EBITDA -0.1015 10
Total:

Growth impulse

Title Value Grade
Profit growth, % 51.38 10
Share price growth, % -489.7 0
Dividend growth, % 0 0
Total:

Insider trading

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
14.03.2024 18.03.2024 Lettmann Jason
CHIEF EXECUTIVE OFFICER
Buy 11.31 49 764 4400 0 0.01 link

Main owners

Institutions Volume Share, %
venBio Partners LLC 9699925 19.34
FMR, LLC 7472821 14.9
Vivo Capital, LLC 4220048 8.41
Redmile Group, LLC 3659264 7.3
Cormorant Asset Management, LP 3142079 6.27
Orbimed Advisors LLC. 3095000 6.17
Blackrock Inc. 2235093 4.46
Vestal Point Capital, LP 1655000 3.3
Vanguard Group Inc 1502409 3
MPM BioImpact Capital LLC 1264759 2.52

Contained in ETF

ETF Share, % Profitability for 1 year, % Dividends, %
Inspire Small/Mid Cap ETF 0.23 51.59 1.19

Similar companies



Company management

Head Job title Payment Year of birth
Dr. Jaume Pons Ph.D. Founder, President, Director & Chief Scientific Officer 856.29k 1967 (57 years)
Dr. Sophia Randolph M.D., Ph.D. Chief Medical Officer & Director 637.24k 1968 (56 years)
Dr. Michael Chang Ph.D. Vice President of Operations N/A
Ms. Shelly Pinto Senior VP of Finance & Chief Accounting Officer 508.26k 1977 (47 years)
Dr. Corey S. Goodman Ph.D. Executive Chairman 84k 1952 (72 years)
Mr. Peter S. Garcia M.B.A. Chief Financial Officer 631.11k 1962 (62 years)
Dr. Athanasios Tsiatis M.D. Senior Vice President of Clinical Development N/A
Dr. Christopher Byrd J.D., Ph.D. General Counsel N/A
Mr. Jason W. Lettmann CEO & Director 60.5k 1977 (47 years)
Dr. Lin Yeong-Liang M.D., M.S. Senior Vice President of Drug Safety & Pharmacovigilance N/A

About company

Address: United States, Burlingame, CA , 866 Malcolm Road - open in Google maps, open in Yandex maps
Website: http://www.alxoncology.com
Phone: +650 466 7125